Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | FURIN | P09958 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | BAX | Q07812 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163058 | 1.00 | RECQL (0.56) | RECQLPARP10F2F10FURIN | |
| SCHEMBL1163061 | 1.00 | RECQL (0.56) | RECQLPARP10F2F10FURIN | |
| SCHEMBL347217 | 0.83 | RECQL (0.64) | RECQLF2F10TSHRALDH1A1 | |
| SCHEMBL10001025 | 0.83 | RECQL (0.64) | RECQLF2F10TSHRALDH1A1 | |
| SCHEMBL347216 | 0.83 | RECQL (0.64) | RECQLF2F10TSHRALDH1A1 | |
| SCHEMBL11844414 | 0.81 | RECQL (0.79) | RECQLPLAUALDH1A1 | |
| SCHEMBL11844408 | 0.81 | RECQL (0.79) | RECQLPLAUALDH1A1 | |
| SCHEMBL28990052 | 0.81 | RECQL (0.79) | RECQLPLAUALDH1A1 | |
| SCHEMBL17412169 | 0.80 | RECQL (0.61) | RECQLSMN1; SMN2KMT2A | |
| SCHEMBL6675297 | 0.80 | PARP10 (0.59) | RECQLPARP10F2ST14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2789615-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140107151-A1 | TYROSINE KINASE INHIBITORS | Principia Biophama Inc. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2012158810-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2464647-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | RECQL 1634/4885PARP10 897/4885F2 4224/4885 |
| US-20140107151-A1 | TYROSINE KINASE INHIBITORS | BMX, BLK, ITK | RECQL 3029/4885PARP10 1387/4885F2 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.